肺动脉高压代谢重编程及其治疗靶点的研究进展
Advances in Research on Metabolic Reprogramming and Therapeutic Targets in Pulmonary Arterial Hypertension
DOI: 10.12677/acm.2026.161227, PDF,   
作者: 刘志华*：赣南医科大学第一附属医院心血管内科，江西 赣州；肖根发#：赣南医科大学第一附属医院心脏医学中心，江西 赣州
关键词: 肺动脉高压；代谢重编程；糖酵解；脂肪酸氧化；精氨酸；Pulmonary Hypertension； Metabolic Reprogramming； Glycolysis； Fatty Acid Oxidation； Arginine
摘要: 肺动脉高压(PH)是一种以肺动脉压力升高和血管重塑为特征的严重致命性疾病，其病因多样且发病机制未明，当前药物治疗效果有限，需要深入探讨其分子机制以寻找新的诊断和治疗靶点。近年来，代谢重编程被发现是PH发病机制中的关键环节，涉及糖酵解增强、乳酸蓄积、脂肪酸氧化减弱、胆固醇及胆汁酸代谢失衡以及氨基酸代谢异常。本文系统综述了PH中代谢重编程的最新研究进展，分析各代谢物及代谢通路在PH发生发展中的作用机制，并探讨可能的治疗靶点，为未来PH的诊疗及长期管理提供理论依据和研究方向。
Abstract: Pulmonary Hypertension (PH) is a severe and life-threatening disease characterized by elevated pulmonary arterial pressure and vascular remodeling. It has diverse etiologies and an unclear pathogenesis, with limited efficacy of current pharmacotherapies. Therefore, in-depth exploration of its molecular mechanisms is required to identify new diagnostic and therapeutic targets. In recent years, metabolic reprogramming has been identified as a key link in the pathogenesis of PH, involving enhanced glycolysis, lactic acid accumulation, impaired fatty acid oxidation, dysregulated cholesterol and bile acid metabolism, as well as abnormal amino acid metabolism. This review systematically summarizes the latest research advances in metabolic reprogramming in PH, analyzes the mechanisms by which various metabolites and metabolic pathways contribute to the development and progression of PH, and discusses potential therapeutic targets. It aims to provide a theoretical basis and research directions for the future diagnosis, treatment, and long-term management of PH.
文章引用：刘志华, 肖根发. 肺动脉高压代谢重编程及其治疗靶点的研究进展[J]. 临床医学进展, 2026, 16(1): 1783-1790. https://doi.org/10.12677/acm.2026.161227

参考文献

[1] Humbert, M., Kovacs, G., Hoeper, M.M., Badagliacca, R., Berger, R.M.F., et al. (2022) 2022 ESC/ERS Guidelines for the Diagnosis and Treatment of Pulmonary Hypertension. European Heart Journal, 43, 3618-3731.
[2] Mocumbi, A., Humbert, M., Saxena, A., Jing, Z., Sliwa, K., Thienemann, F., et al. (2024) Pulmonary Hypertension. Nature Reviews Disease Primers, 10, Article No. 1. [Google Scholar] [CrossRef] [PubMed]
[3] Chin, K.M., Gaine, S.P., Gerges, C., Jing, Z., Mathai, S.C., Tamura, Y., et al. (2024) Treatment Algorithm for Pulmonary Arterial Hypertension. European Respiratory Journal, 64, Article 2401325. [Google Scholar] [CrossRef] [PubMed]
[4] Cao, Y., Zhang, X., Wang, L., Yang, Q., Ma, Q., Xu, J., et al. (2019) PFKFB3-Mediated Endothelial Glycolysis Promotes Pulmonary Hypertension. Proceedings of the National Academy of Sciences, 116, 13394-13403. [Google Scholar] [CrossRef] [PubMed]
[5] Gong, X., Sheng, Y., Zhang, G., Kang, S., Liu, X., Wang, Y., et al. (2025) Notoginsenoside R1 Improved Hypoxic Pulmonary Hypertension by Inhibiting Glycolysis-Mediated Pulmonary Arterial Vascular Remodeling. Canadian Respiratory Journal, 2025, Article 2884885. [Google Scholar] [CrossRef] 
[6] Zhang, C., Sun, Y., Guo, Y., Xu, J. and Zhao, H. (2023) JMJD1C Promotes Smooth Muscle Cell Proliferation by Activating Glycolysis in Pulmonary Arterial Hypertension. Cell Death Discovery, 9, Article No. 98. [Google Scholar] [CrossRef] [PubMed]
[7] Shi, W., Chen, L., Zhang, W., He, P., Zhang, Y., Yan, K., et al. (2025) YAP-Mediated Glycolysis Promotes Pulmonary Arterial Smooth Muscle Cell Proliferation in Pulmonary Arterial Hypertension. Journal of Biological Chemistry, 301, Article 110836. [Google Scholar] [CrossRef] 
[8] Meng, H., Deng, Y., Liao, J., Wu, D., Li, L., Chen, X., et al. (2024) β-Catenin Mediates Monocrotaline-Induced Pulmonary Hypertension via Glycolysis in Rats. BMC Cardiovascular Disorders, 24, Article No. 381. [Google Scholar] [CrossRef] [PubMed]
[9] Chen, M., Li, H., Li, Y., Luo, Y., He, Y., Shui, X., et al. (2024) Glycolysis Modulation: New Therapeutic Strategies to Improve Pulmonary Hypertension (Review). International Journal of Molecular Medicine, 54, Article No. 115. [Google Scholar] [CrossRef] [PubMed]
[10] Wu, D., Wang, S., Wang, F., Zhang, Q., Zhang, Z. and Li, X. (2024) Lactate Dehydrogenase a (LDHA)-Mediated Lactate Generation Promotes Pulmonary Vascular Remodeling in Pulmonary Hypertension. Journal of Translational Medicine, 22, Article No. 738. [Google Scholar] [CrossRef] [PubMed]
[11] Peng, T.Y., Lu, J.M., Zheng, X.L., et al. (2025) The Role of Lactate Metabolism and Lactylation in Pulmonary Arterial Hypertension. Respiratory Research, 26, Article No. 99. [Google Scholar] [CrossRef] [PubMed]
[12] Tuineau, M.N., Herbert, L.M., Garcia, S.M., Resta, T.C. and Jernigan, N.L. (2024) Enhanced Glycolysis Causes Extracellular Acidification and Activates Acid-Sensing Ion Channel 1a in Hypoxic Pulmonary Hypertension. American Journal of Physiology-Lung Cellular and Molecular Physiology, 327, L439-L451. [Google Scholar] [CrossRef] [PubMed]
[13] Sun, F., Li, W., Du, R., Liu, M., Cheng, Y., Ma, J., et al. (2025) Impact of Glycolysis Enzymes and Metabolites in Regulating DNA Damage Repair in Tumorigenesis and Therapy. Cell Communication and Signaling, 23, Article No. 44. [Google Scholar] [CrossRef] [PubMed]
[14] Rao, D., Stunnenberg, J.A., Lacroix, R., Dimitriadis, P., Kaplon, J., Verburg, F., et al. (2023) Acidity-Mediated Induction of FoxP3+ Regulatory T Cells. European Journal of Immunology, 53, Article 2250258. [Google Scholar] [CrossRef] [PubMed]
[15] Cheng, Y., Tian, Y.N., Huang, M., Xu, J.P., Cao, W.J., et al. (2025) Hydrogen Sulfide Ameliorates Hypoxic Pulmonary Hypertension in Rats by Inhibiting Aerobic Glycolysis-Pyroptosis. Sheng li xue bao [Acta physiologica Sinica], 77, 465-471.
[16] Chen, A., Chen, Z., Huang, B., Lian, G., Luo, L. and Xie, L. (2025) Hypoxia-Induced Histone Lactylation Promotes Pulmonary Arterial Smooth Muscle Cells Proliferation in Pulmonary Hypertension. Molecular and Cellular Biochemistry, 480, 5685-5697. [Google Scholar] [CrossRef] [PubMed]
[17] Luo, L., Xiao, L., Lian, G., Wang, H. and Xie, L. (2020) miR-125a-5p Inhibits Glycolysis by Targeting Hexokinase-II to Improve Pulmonary Arterial Hypertension. Aging, 12, 9014-9030. [Google Scholar] [CrossRef] [PubMed]
[18] Mansoor, M. and Ibrahim, A.F. (2025) Emerging Mechanistic Insights and Therapeutic Strategies for Pulmonary Arterial Hypertension: A Focus on Right Ventricular Dysfunction and Novel Treatment Pathways. Biomedicines, 13, Article 600. [Google Scholar] [CrossRef] [PubMed]
[19] Acharya, A.P., Tang, Y., Bertero, T., Tai, Y., Harvey, L.D., Woodcock, C.C., et al. (2021) Simultaneous Pharmacologic Inhibition of Yes-Associated Protein 1 and Glutaminase 1 via Inhaled Poly (Lactic-co-Glycolic) Acid-Encapsulated Microparticles Improves Pulmonary Hypertension. Journal of the American Heart Association, 10, e019091. [Google Scholar] [CrossRef] [PubMed]
[20] Randle, P.J., Garland, P.B., Hales, C.N. and Newsholme, E.A. (1963) The Glucose Fatty-Acid Cycle Its Role in Insulin Sensitivity and the Metabolic Disturbances of Diabetes Mellitus. The Lancet, 281, 785-789. [Google Scholar] [CrossRef] [PubMed]
[21] Bordag, N., Nagy, B.M., Zügner, E., Ludwig, H., Foris, V., Nagaraj, C., et al. (2025) Lipid Ratios for Diagnosis and Prognosis of Pulmonary Hypertension. American Journal of Respiratory and Critical Care Medicine, 211, 1264-1276. [Google Scholar] [CrossRef] [PubMed]
[22] Singh, N., Manhas, A., Kaur, G., Jagavelu, K. and Hanif, K. (2016) Inhibition of Fatty Acid Synthase Is Protective in Pulmonary Hypertension. British Journal of Pharmacology, 173, 2030-2045. [Google Scholar] [CrossRef] [PubMed]
[23] Philip, N., Yun, X., Pi, H., Murray, S., Hill, Z., Fonticella, J., et al. (2024) Fatty Acid Metabolism Promotes TRPV4 Activity in Lung Microvascular Endothelial Cells in Pulmonary Arterial Hypertension. American Journal of Physiology-Lung Cellular and Molecular Physiology, 326, L252-L265. [Google Scholar] [CrossRef] [PubMed]
[24] Agrawal, V., Hemnes, A.R., Shelburne, N.J., Fortune, N., Fuentes, J.L., Colvin, D., et al. (2022) l-Carnitine Therapy Improves Right Heart Dysfunction through Cpt1-Dependent Fatty Acid Oxidation. Pulmonary Circulation, 12, e12107. [Google Scholar] [CrossRef] [PubMed]
[25] Brittain, E.L., Talati, M., Fessel, J.P., Zhu, H., Penner, N., Calcutt, M.W., et al. (2016) Fatty Acid Metabolic Defects and Right Ventricular Lipotoxicity in Human Pulmonary Arterial Hypertension. Circulation, 133, 1936-1944. [Google Scholar] [CrossRef] [PubMed]
[26] Brittain, E.L., Lindsey, A., Burke, K., Agrawal, V., Robbins, I., Pugh, M., et al. (2024) Carnitine Consumption and Effect of Oral Supplementation in Human Pulmonary Arterial Hypertension: A Pilot Study. Pulmonary Circulation, 14, e12425. [Google Scholar] [CrossRef] [PubMed]
[27] Spyropoulos, F., Michael, Z., Finander, B., Vitali, S., Kosmas, K., Zymaris, P., et al. (2021) Acetazolamide Improves Right Ventricular Function and Metabolic Gene Dysregulation in Experimental Pulmonary Arterial Hypertension. Frontiers in Cardiovascular Medicine, 8, Article 662870. [Google Scholar] [CrossRef] [PubMed]
[28] Guo, J., Zhao, J., Wang, J., Li, Y., et al. (2025) Impact of Lipid Profile Alterations on the Right Heart Function and Prognosis in Pre-Capillary Pulmonary Hypertension Patients: A Prospective Cohort Study. Respirology.
[29] Jonas, K. and Kopeć, G. (2019) HDL Cholesterol as a Marker of Disease Severity and Prognosis in Patients with Pulmonary Arterial Hypertension. International Journal of Molecular Sciences, 20, Article 3514. [Google Scholar] [CrossRef] [PubMed]
[30] Campos de Andrade, O.G., Gonçalves de Castro, L.C. and Amado, V.M. (2024) Unveiling the Metabolic Challenges in Pulmonary Arterial Hypertension: Insights into Thyroid, Glycemic, Lipid, and Bone Disorders. Respiratory Medicine, 235, Article 107859. [Google Scholar] [CrossRef] [PubMed]
[31] Umar, S., Ruffenach, G., Moazeni, S., Vaillancourt, M., Hong, J., Cunningham, C., et al. (2020) Involvement of Low-Density Lipoprotein Receptor in the Pathogenesis of Pulmonary Hypertension. Journal of the American Heart Association, 9, e12063. [Google Scholar] [CrossRef] [PubMed]
[32] Jiang, L., Konishi, H., Nurwidya, F., Satoh, K., Takahashi, F., Ebinuma, H., et al. (2016) Deletion of LR11 Attenuates Hypoxia-Induced Pulmonary Arterial Smooth Muscle Cell Proliferation with Medial Thickening in Mice. Arteriosclerosis, Thrombosis, and Vascular Biology, 36, 1972-1979. [Google Scholar] [CrossRef] [PubMed]
[33] Lin, J., Pan, Z., Sun, J., Wang, X., Yin, D., Huo, C., et al. (2024) PCSK9 Inhibitor Alleviates Experimental Pulmonary Fibrosis-Induced Pulmonary Hypertension via Attenuating Epithelial-Mesenchymal Transition by Suppressing Wnt/β-Catenin Signaling in Vivo and in Vitro. Frontiers in Medicine, 11, Article 1509168. [Google Scholar] [CrossRef] [PubMed]
[34] Harvey, L.D., Alotaibi, M., Tai, Y., Tang, Y., Kim, H.J., Kelly, N.J., et al. (2025) Lysosomal Dysfunction and Inflammatory Sterol Metabolism in Pulmonary Arterial Hypertension. Science, 387, eadn7277. [Google Scholar] [CrossRef] [PubMed]
[35] Alotaibi, M., Harvey, L.D., Nichols, W.C., et al. (2024) Pulmonary Primary Oxysterol and Bile Acid Synthesis as a Predictor of Outcomes in Pulmonary Arterial Hypertension.
[36] Chen, X., Li, L., Deng, Y., Liao, J., Meng, H., Liang, L., et al. (2025) Inhibition of Glutaminase 1 Reduces M1 Macrophage Polarization to Protect against Monocrotaline-Induced Pulmonary Arterial Hypertension. Immunology Letters, 272, Article 106974. [Google Scholar] [CrossRef] [PubMed]
[37] Rachedi, N.S., Tang, Y., Tai, Y., Zhao, J., Chauvet, C., Grynblat, J., et al. (2024) Dietary Intake and Glutamine-Serine Metabolism Control Pathologic Vascular Stiffness. Cell Metabolism, 36, 1335-1350.e8. [Google Scholar] [CrossRef] [PubMed]
[38] Yegambaram, M., Sun, X., Lu, Q., Flores, A.G., Zemskova, M., Soto, J., et al. (2025) C-Myc Promotes Metabolic Reprogramming in Pulmonary Hypertension via the Stimulation of Glutaminolysis and the Reductive Tricarboxylic Acid Cycle. Redox Biology, 85, Article 103765. [Google Scholar] [CrossRef] [PubMed]
[39] Liu, X., Zhang, L. and Zhang, W. (2022) Metabolic Reprogramming: A Novel Metabolic Model for Pulmonary Hypertension. Frontiers in Cardiovascular Medicine, 9, Article 957524. [Google Scholar] [CrossRef] [PubMed]
[40] Stam, K., van Duin, R.W., Uitterdijk, A., Krabbendam-Peters, I., Sorop, O., Danser, A.H.J., et al. (2018) Pulmonary Microvascular Remodeling in Chronic Thrombo-Embolic Pulmonary Hypertension. American Journal of Physiology-Lung Cellular and Molecular Physiology, 315, L951-L964. [Google Scholar] [CrossRef] [PubMed]
[41] Giaid, A. and Saleh, D. (1995) Reduced Expression of Endothelial Nitric Oxide Synthase in the Lungs of Patients with Pulmonary Hypertension. New England Journal of Medicine, 333, 214-221. [Google Scholar] [CrossRef] [PubMed]
[42] Nara, A., Nagai, H., Shintani-Ishida, K., Ogura, S., Shimosawa, T., Kuwahira, I., et al. (2015) Pulmonary Arterial Hypertension in Rats Due to Age-Related Arginase Activation in Intermittent Hypoxia. American Journal of Respiratory Cell and Molecular Biology, 53, 184-192. [Google Scholar] [CrossRef] [PubMed]
[43] Gemici Karaaslan, B., Kiykim, A., Burtecene, N., Gokden, M., Cansever, M.S., Hopurcuoglu, D., et al. (2025) Amino Acid Metabolism and Immune Dysfunction in Urea Cycle Disorders: T and B Cell Perspectives. Journal of Inherited Metabolic Disease, 48, e70009. [Google Scholar] [CrossRef] [PubMed]
[44] Piao, L., Fang, Y., Parikh, K., Ryan, J.J., Toth, P.T. and Archer, S.L. (2013) Cardiac Glutaminolysis: A Maladaptive Cancer Metabolism Pathway in the Right Ventricle in Pulmonary Hypertension. Journal of Molecular Medicine, 91, 1185-1197. [Google Scholar] [CrossRef] [PubMed]
[45] Yang, Z., Li, P., Yuan, Q., Wang, X., Ma, H. and Zhuan, B. (2023) Inhibition of miR-4640-5p Alleviates Pulmonary Hypertension in Chronic Obstructive Pulmonary Disease Patients by Regulating Nitric Oxide Synthase 1. Respiratory Research, 24, Article No. 92. [Google Scholar] [CrossRef] [PubMed]

为你推荐